pSivida

Watertown, United States Founded: 1987 • Age: 39 yrs Listed
Drug delivery systems

About pSivida

pSivida is a publicly listed company based in Watertown (United States) founded in 1987. Drug delivery systems. The company has 49 employees. pSivida has completed 1 acquisition, including EyePoint Pharmaceuticals. Its chief executive, as recorded, is Paul Ashton. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is PSIVIDA CORP. Its competitors include Rezolute, Aviceda Therapeutics and EyePoint Pharmaceuticals; 1 of its 3 listed competitors has raised funding.

Company details

Founded in 1987 and based in Watertown, United States, pSivida operates in the biotechnology sector, focusing on sustained-release drug delivery technologies. Products such as Durasert and Tethadur are licensed to partners including Pfizer and Alimera Sciences for applications in ophthalmology. FDA-approved offerings like ILUVIEN for diabetic macular edema and Retisert for uveitis are utilized through intravitreal implants, with administration controlled for months or years.

  • Headquarters Watertown, United States
  • Employees 49
  • Stage Public
  • Sectors
    Healthcare
  • Website psivida.com
  • Social LinkedIn X
  • Legal Name Psivida Corp.
Operational Areas
Key Metrics
  • Annual Revenue
    $3.1 M (USD)
    210
    as on Dec 31, 2024
  • Net Profit
    -$130.87 M (USD)
    -85
    as on Dec 31, 2024
  • EBITDA
    -$145.85 M (USD)
    -94
    as on Dec 31, 2024
  • Latest Funding Round
    $60.5M (USD), Post-IPO

    Mar 2018

  • Investors
    RA Capital

    & 2 more

  • Employee Count
    49
  • Investments & Acquisitions

Funding Insights of pSivida

  • Total Rounds 4
  • Last Round Post-IPO β€” $60.5M
  • First Round $40M

    (Jul 2012)

  • Investors Count 3

All 4 funding rounds of pSivida with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2018$20MDebt – Conventional––
Mar 2018$60.5MPost-IPO––
Mar 2014$7MPost-IPO––
Jul 2012$40MPost-IPO––
–
Valuation history

3 investors in total: 3 institutional.

Investors in pSivida

pSivida has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, SWK Holdings and EW Healthcare Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
ewhealthcare.comNew York, United States
Investments and advisory services are provided by the holding company.
2009swkhold.comDallas, United States
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
2004racap.comBoston, United States
Premium access

Investor details for pSivida

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of pSivida

87 people are tracked at pSivida (44 in leadership, 14 in board & advisors, 29 in team); the tracked headcount is 49.

NameRoleGroup
Paul Ashton
CEOLeadership
Bridget Eastes
Controller, DirectorLeadership
Erika Boucher
IT Business Relationship DirectorLeadership
Ramiro Ribeiro
Chief Medical OfficerLeadership
Joseph Clements
Senior Director Quality ControlLeadership
Raj Dasari
Sr. Director, Validation EngineeringLeadership
Brian Burke-Green
Associate Director Regulatory SubmissionsLeadership
Keyur Patel
Vice President, Head Medical AffairsLeadership
Monica Roy
Vice President, Clinical Development -ophthalmologyLeadership
Jennifer Leonard
Chief People Officer & SVP, ITLeadership
Jay S. Duker
President & CEOLeadership
George O. Elston
CFO & Head of Corporate DevelopmentLeadership
Isabelle Lefebvre
Chief Regulatory OfficerLeadership
Christine Greenough
Senior Director , Global Quality AssuranceLeadership
Rich Welch
Associate Director, Application SupportLeadership
Ron Honig
Chief Legal Officer & Company SecretaryLeadership
Scott Jones
Chief Commercial OficerLeadership
Theresa Dibiase
Associate Director, Talent AcquisitionLeadership
Craig Chatham
Head Of Financial Planning And Analysis And Financial SystemsLeadership
Joe Musiak
Senior Director, Facilities & EngineeringLeadership

67 more people are available in the full profile.

Premium access

Complete people profiles for pSivida

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by pSivida

pSivida has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EyePoint Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Small molecule therapeutics for ophthalmic disorders are developed.
eyepointpharma.comWatertown, United States1987Mar 2018$55M
Premium access

Complete acquisition details for pSivida

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of pSivida

5 dated milestones of pSivida across 31 years, from founding to its latest funding, stage changes and deals.

  1. Founded pSivida is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $40.0M.
  4. Funding Latest funding round, Post-IPO, of $60.5M.
  5. Acquisition Acquires EyePoint Pharmaceuticals.

Competitors of pSivida

pSivida has 3 listed competitors in our database, 1 of them funded. They include Rezolute, Aviceda Therapeutics and EyePoint Pharmaceuticals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
rezolutebio.com2012Denver, United States51
Therapies for metabolic and orphan diseases are developed by Rezolute.
avicedarx.com2018Cambridge, United States$254.66M
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
eyepointpharma.com1987Watertown, United States49
Small molecule therapeutics for ophthalmic disorders are developed.
Premium access

Detailed competitors of pSivida

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of pSivida

Websites that share an audience with pSivida (psivida.com).

Similar websites

Websites whose visitors overlap most with pSivida. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
neuralstem.com
neuralstem.com
100%
–
alimerasciences.com
96%
View details
novartis.net
novartis.net
92%
–
ethypharm.com
92%
3.5K#6,712,435View details
retinavitreous.com
retinavitreous.com
60%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 10 similar websites and full traffic analytics for pSivida

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Ophthalmology

3 companies that operate in the same segment as pSivida (Ophthalmology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of a wide range of eye care products
1945Fort Worth, Texas, United StatesUSD 171.61 MUSD 24.69 B25,941
Genetic medicines are developed by 4DMT for transformative therapies.
2013Emeryville, California, United StatesUSD 186.59 MUSD 85.21 M227
Developer of antibodies to treat complement-mediated neurodegenerative diseases
2011San Francisco, California, United StatesUSD 256 M100
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Psivida

Premium access

Complete news archive for pSivida

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about pSivida

pSivida was founded in 1987 and raised its 1st funding round 25 years after it was founded.

pSivida is headquartered in Watertown, United States.

Paul Ashton is the CEO of pSivida, as recorded in our data.

pSivida has 49 employees.

Annual revenue of pSivida is $3.1M as on Dec 31, 2024.

Founded in 1987 and based in Watertown, United States, pSivida operates in the biotechnology sector, focusing on sustained-release drug delivery technologies. Products such as Durasert and Tethadur are licensed to partners including Pfizer and Alimera Sciences for applications in ophthalmology. FDA-approved offerings like ILUVIEN for diabetic macular edema and Retisert for uveitis are utilized through intravitreal implants, with administration controlled for months or years.

pSivida's top competitors include EyePoint Pharmaceuticals, Rezolute and Aviceda Therapeutics.

pSivida has made 1 acquisition, including EyePoint Pharmaceuticals.

pSivida has 3 investors. Key investors include RA Capital, SWK Holdings, and EW Healthcare Partners.

pSivida operates through Psivida Corp..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available